Over the past seven years, Celgene has emerged as one of the most active and creative deal-makers in the biopharma industry.
The Boston Consulting Group’s Biopharma Partnering Survey and Benchmarking analysis examines BD activity and perceptions across the industry, and their 2014 analysis was very telling.
